Qnexa phentermine/topiramate: Extension study data
Top-line data from the double-blind, 52-week SEQUEL (OB-305) extension study of the 56-week Phase III CONQUER (OB-303) trial in 675 obese or overweight patients showed that both doses of once-daily oral Qnexa phentermine/topiramate (7.5 mg/46 mg or 15 mg/92 mg) met the co-primary endpoints of mean percentage weight loss from baseline and percentage of subjects achieving >=5% , >=10% and >=15% weight loss vs. placebo at 108 weeks. Specifically, average weight loss for the mid- and high-dose groups was 10.4% and 11.4%, respectively, vs. 2.5% for placebo (p<0.0001 for both). The proportion of patients losing >=5%, >=10% and >=15% of their initial body weight was 75%, 50% and 24% for mid-dose Qnexa; 79%, 54% and 32% for high-dose Qnexa; and 30%, 12% and 7% for placebo (p<0.0001 for all). ...